Amandine Crombé1,2,3, François Le Loarer4,5, François Cornelis6, Eberhardt Stoeckle7, Xavier Buy8, Sophie Cousin9, Antoine Italiano4,9, Michèle Kind8. 1. Department of Diagnostic and Interventional Radiology, Institut Bergonie, Comprehensive Cancer Center, 229 cours de l'Argonne, F-33000, Bordeaux, France. amandine.crombe@ens-lyon.fr. 2. Modelisation in Oncology (MOnc) Team, INRIA Bordeaux-Sud-Ouest, CNRS UMR 5251 & Université de Bordeaux, F-33405, Talence, France. amandine.crombe@ens-lyon.fr. 3. University of Bordeaux, F-33000, Bordeaux, France. amandine.crombe@ens-lyon.fr. 4. University of Bordeaux, F-33000, Bordeaux, France. 5. Department of Pathology, Institut Bergonie, F-33000, Bordeaux, France. 6. Department of Radiology, Tenon Hospital, Sorbonne University, APHP, F-75020, Paris, France. 7. Department of Surgery, Institut Bergonie, F-33000, Bordeaux, France. 8. Department of Diagnostic and Interventional Radiology, Institut Bergonie, Comprehensive Cancer Center, 229 cours de l'Argonne, F-33000, Bordeaux, France. 9. Department of Medical Oncology, Institut Bergonie, F-33000, Bordeaux, France.
Abstract
OBJECTIVES: To determine the acquisition delay after gadolinium-chelate injection that optimizes the prediction of the histological response during anthracycline-based neoadjuvant chemotherapy (NAC) for locally advanced high-grade soft-tissue sarcomas (STS). METHODS: Thirty patients (mean age 62 years) were included in this IRB-approved study. All patients received 5-6 cycles of NAC followed by surgery. A good response was defined as ≤ 10% viable cells on histological analysis of the surgical specimen. DCE-MRI was performed before treatment (MRI0) and after two cycles (MRI1). Images were obtained every 8 s. Change in contrast enhancement (CE) between MRI0 and MRI1 was calculated for each acquisition delay 't' on the whole tumor volume. Area under the receiver-operating characteristics curves (AUROC) for change in CE was calculated at each acquisition delay, as well as the accuracy of the Choi criteria. RESULTS: There were 22 (73.3%) poor responders. Acquisition delay had a significant effect on change in CE and on the response status according to Choi (p = 0.0014 and 0.0270, respectively). The highest AUROC was obtained at t = 58 s (0.792) with an optimal threshold of a -30.5% decrease in CE. At t = 58 s, accuracy to predict a poor response was 82.8% above this threshold, while it was 72.4% and 70% with no objective response according to the Choi criteria and RECIST1.1, respectively. CONCLUSION: Optimization of acquisition delay after injection to estimate change in CE improves the prediction of histological response. For STS undergoing NAC, a 60-s delay can be recommended with MRI. KEY POINTS: • Accuracy of response criteria based on contrast enhancement, like the Choi criteria, is dependent on the acquisition delay after gadolinium-chelate injection. • DCE-MRI helps determine the optimal acquisition delay after gadolinium-chelate injection for improving evaluation of tumor response. • In soft tissue sarcoma, an acquisition delay at 60 s optimizes the evaluation of the response and accuracy of the Choi criteria.
OBJECTIVES: To determine the acquisition delay after gadolinium-chelate injection that optimizes the prediction of the histological response during anthracycline-based neoadjuvant chemotherapy (NAC) for locally advanced high-grade soft-tissue sarcomas (STS). METHODS: Thirty patients (mean age 62 years) were included in this IRB-approved study. All patients received 5-6 cycles of NAC followed by surgery. A good response was defined as ≤ 10% viable cells on histological analysis of the surgical specimen. DCE-MRI was performed before treatment (MRI0) and after two cycles (MRI1). Images were obtained every 8 s. Change in contrast enhancement (CE) between MRI0 and MRI1 was calculated for each acquisition delay 't' on the whole tumor volume. Area under the receiver-operating characteristics curves (AUROC) for change in CE was calculated at each acquisition delay, as well as the accuracy of the Choi criteria. RESULTS: There were 22 (73.3%) poor responders. Acquisition delay had a significant effect on change in CE and on the response status according to Choi (p = 0.0014 and 0.0270, respectively). The highest AUROC was obtained at t = 58 s (0.792) with an optimal threshold of a -30.5% decrease in CE. At t = 58 s, accuracy to predict a poor response was 82.8% above this threshold, while it was 72.4% and 70% with no objective response according to the Choi criteria and RECIST1.1, respectively. CONCLUSION: Optimization of acquisition delay after injection to estimate change in CE improves the prediction of histological response. For STS undergoing NAC, a 60-s delay can be recommended with MRI. KEY POINTS: • Accuracy of response criteria based on contrast enhancement, like the Choi criteria, is dependent on the acquisition delay after gadolinium-chelate injection. • DCE-MRI helps determine the optimal acquisition delay after gadolinium-chelate injection for improving evaluation of tumor response. • In soft tissue sarcoma, an acquisition delay at 60 s optimizes the evaluation of the response and accuracy of the Choi criteria.
Entities:
Keywords:
Chemotherapy; Magnetic resonance imaging; Response evaluation criteria in solid tumors; Sarcoma
Authors: Rolf D Issels; Lars H Lindner; Jaap Verweij; Peter Wust; Peter Reichardt; Baard-Christian Schem; Sultan Abdel-Rahman; Soeren Daugaard; Christoph Salat; Clemens-Martin Wendtner; Zeljko Vujaskovic; Rüdiger Wessalowski; Karl-Walter Jauch; Hans Roland Dürr; Ferdinand Ploner; Andrea Baur-Melnyk; Ulrich Mansmann; Wolfgang Hiddemann; Jean-Yves Blay; Peter Hohenberger Journal: Lancet Oncol Date: 2010-04-29 Impact factor: 41.316
Authors: Silvia Stacchiotti; Paolo Verderio; Antonella Messina; Carlo Morosi; Paola Collini; Antonio Llombart-Bosch; Javier Martin; Alessandro Comandone; Jurado Cruz; Andrea Ferraro; Giovanni Grignani; Sara Pizzamiglio; Vittorio Quagliuolo; Piero Picci; Sergio Frustaci; Angelo Paolo Dei Tos; Paolo G Casali; Alessandro Gronchi Journal: Cancer Date: 2012-05-17 Impact factor: 6.860
Authors: Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; William D Tap; Sarah M Dry; David Elashoff; Kira Chow; Vladimir Evilevitch; Jeff J Eckardt; Michael E Phelps; Wolfgang A Weber; Fritz C Eilber Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Catherina S P van Rijswijk; Maartje J A Geirnaerdt; Pancras C W Hogendoorn; Johannes L Peterse; Frits van Coevorden; Antonie H M Taminiau; Rob A E M Tollenaar; Bin B R Kroon; Johan L Bloem Journal: Eur Radiol Date: 2003-01-08 Impact factor: 5.315